2023年

  1. Tamefusa K, Ochi M, Ishida H, Shiwaku T, Kanemitsu K, Fujiwara K, Tatebe Y, Matsumoto N, Washio K, Tsukahara H. Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study. Eur J Haematol. 2023 Dec 28. Online ahead of print.
  2. Shiwaku T, Ishida H, Tatebe Y, Tamefusa K, Ochi M, Fujiwara K, Kubo T, Nakata E, Washio K, Tsukahara H. A Boy Safely Treated with Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Osteolysis. Acta Medica Okayama.2023. Vol. 77, No. 4, pp. 439-442.
  3. Hagiya H, Osaki Y, Yamamoto M, Niimura T, Harada K, Higashionna T, Hamano H, Zamami Y, Hinotsu S, Koyama T. Global trends of seasonal influenza-associated mortality in 2001-2018: A longitudinal epidemiological study. J Infect. 2023 Jun 16:S0163-4453(23)00334-1. Online ahead of print.
  4. Tsujinaka K, Izawa-Ishizawa Y, Miyata K, Yoshioka T, Oomine K, Nishi H, Kondo M, Itokazu S, Miyata T, Niimura T, Sato M, Aizawa F, Yagi K, Chuma M, Zamami Y, Goda M, Ishizawa K. Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection. Biomed Pharmacother. 2023 Sep 16;167:115504. Online ahead of print.
  5. Yoshioka T, Goda M, Kanda M, Itobayashi S, Sugimoto Y, Izawa-Ishizawa Y, Yagi K, Aizawa F, Miyata K, Niimura T, Hamano H, Sakurada T, Zamami Y, Ishizawa K. Valproic acid treatment attenuates cisplatin-induced kidney injury by suppressing proximal tubular cell damage. Clin Transl Sci. 2023 Sep 12.Online ahead of print.
  6. Neishi M, Hamano H, Niimura T, Denda M, Yagi K, Miyata K, Lin TJ, Higashionna T, Goda M, Zamami Y, Ishizawa K, Nawa H. Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases. Toxicol Appl Pharmacol. 2023 Jul 21:116632. Online ahead of print.
  7. Tsukasa Higashionna, Keisaku Harada, Akinari Maruo, Takahiro, Niimura, Elizabeth Tan, Quynh Thi Vu, Takayoshi Kawabata, Soichiro Ushio, Hirofumi Hamano, Makoto Kajizono, Yoshito Zamami, Keisuke Ishizawa, Ko Harada, Shiro Hinotsu, Mitsunobu R. Kano, Hideharu Hagiya, Toshihiro Koyama. Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational Analysis. Cancers 2023, 15(15), 3786
  8. Takashi Bando, Hirofumi Hamano, Takahiro Niimura, Naoto Okada, Masateru Kondo, Yuki Izumi, Shunsuke Ishida, Toshihiko Yoshioka, Mizuho Asada, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Yuki Izawa-Ishizawa, Momoyo Azuma, Hiroaki Yanagawa, Yoshikazu Tasaki, Keisuke Ishizawa. Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases. Acta Medica Okayama, in press.
  9. Niimura T, Goda M, Miyata K, Matsumoto J, Yoshioka T, Hamano H, Aizawa F, Yagi K, Izawa-Ishizawa Y, Zamami Y, Ishizawa K.
    Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination. Front. Drug Saf. Regul. In press.
  10. Imakura T, Sato S, Koyama K, Ogawa H, Niimura T, Murakami K, Yamashita Y, Haji K, Naito N, Kagawa K, Kawano H, Zamami Y, Ishizawa K, Nishioka Y. A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis. Respir Res. 2023 Jun 2;24(1):148.
  11. Niimura T, Miyata K, Hamano H, Nounin Y, Unten H, Yoshino M, Mitsuboshi S, Aizawa F, Yagi K, Koyama T, Goda M, Kanda Y, Izawa-Ishizawa Y, Zamami Y, Ishizawa K. Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase). Drug Saf. 2023 Jun;46(6):545-552.
  12. Mitsuboshi S, Hamano H, Niimura T, Ozaki AF, Patel PM, LIN TJ, Tanaka Y, Kimura I, Iwata N, Shiromizu S, Chuma M, Koyama T, Yamanishi Y, Kanda Y, Ishizawa K, Zamami Y. Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics. Int J Cancer. In press.
  13. Ishida H, Imamura T, Tatebe Y, Ishihara T, Sakaguchi K, Suenobu S, Sato A, Hashii Y, Deguchi T, Takahashi Y, Hasegawa D, Miyamura T, Iguchi A, Kato K, Saito-Moriya A, Hara J, Horibe K. lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol. Br J Haematol. 2023 Jun;201(6):1200-1208.
2022年
  1. Ando-Matsuoka R, Yagi K, Takaoka M, Sakajiri Y, Shibata T, Sawada R, Maruo A, Miyata K, Aizawa F, Hamano H, Niimura T, Izawa-Ishizawa Y, Goda M, Sakaguchi S, Zamami Y, Yamanishi Y, Ishizawa K. Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells. Drug Dev Res. 2023 Feb;84(1):75-83.
  2. Yagi K, Maruo A, Ishida S, Aizawa F, Ushio S, Sakaguchi S, Kajizono M, Niimura T, Goda M, Hamano H, Izawa-Ishizawa Y, Zamami Y, Ishizawa K. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study. Clin Exp Med. 2023 Feb 4. Online ahead of print.
  3. Mitsuboshi S, Hamano H, Kuniki Y, Niimura T, Chuma M, Ushio S, Lin TJ, Matsumoto J, Takeda T, Kajizono M, Zamami Y, Ishizawa K. Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases. Ann Pharmacother. 2023 Feb 27. Online ahead of print.
  4. Tamefusa K, Ishida H, Kanamitsu K, Ochi M, Fujiwara K, Tatebe Y, Aoe M, Nodomi S, Washio K. Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication.
    Pediatr Blood Cancer. 2022: e30108. Online ahead of print.
  5. Matsumoto J, Nishimoto A, Watari S, Ueki H, Shiromizu S, Iwata N, Takeda T, Ushio S, Kajizono M, Fujiyoshi M, Koyama T, Araki M, Wada K, Zamami Y, Nasu Y, Ariyoshi N. Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma. Mol Cell Biochem. 2022 Dec 26. Online ahead of print.
  6. Niimura T, Zamami Y, Miyata K, Mikami T, Asada M, Fukushima K, Yoshino M, Mitsuboshi S, Okada N, Hamano H, Sakurada T, Matsuoka-Ando R, Aizawa F, Yagi K, Goda M, Chuma M, Koyama T, Izawa-Ishizawa Y, Yanagawa H, Fujino H, Yamanishi Y, Ishizawa K. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the United States Food and Drug Administration Adverse Event Reporting System. J Clin Pharmacol. 2023 Apr;63(4):473-479.
  7. Esumi S, Ushio S, Zamami Y. Polypharmacy in Older Adults with Alzheimer's Disease. Medicina (Kaunas). 2022; 58(10):1445. Review.
  8. Chuma M, Hamano H, Bando T, Kondo M, Okada N, Izumi Y, Ishida S, Yoshioka T, Asada M, Niimura T, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Kasamo S, Izawa-Ishizawa Y, Azuma M, Yanagawa H, Tasaki Y, Ishizawa K. Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases. Basic Clin Pharmacol Toxicol. 2022;131(6):525-535.
  9. Nawa H, Hamano H, Niimura T, Miyata K, Yagi K, Goda M, Zamami Y, Ishizawa K. Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects. Clin Transl Sci. 2022 Dec;15(12):2982-2988.
  10. Tatebe Y, Ushio S, Esumi S, Sada H, Ochi M, Tamefusa K, Ishida H, Fujiwara K, Kanamitsu K, Washio K, Katsube R, Murakawa K, Zamami Y. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children. Pediatr Blood Cancer. 2022; 69(12):e29979.
  11. Koyama T, Higashionna T, Maruo A, Ushio S, Zamami Y, Harada K, Hagiya H. Trends in places and causes of death among centenarians in Japan from 2006 to 2016. Geriatr Gerontol Int. 2022; 22(8):675-680.
  12. Ochi K, Suzawa K, Thu YM, Takatsu F, Tsudaka S, Zhu Y, Nakata K, Takeda T, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Shien T, Okamoto Y, Tomida S, Toyooka S.
    Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast. Cancer Sci. 2022 Oct;113(10):3428-3436.
  13. Matsumoto J, Iwata N, Watari S, Ushio S, Shiromizu S, Takeda T, Hamano H, Kajizono M, Araki M, Nasu Y, Ariyoshi N, Zamami Y.. Adverse Events of Axitinib plus Pembrolizumab versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in FDA Adverse Event Reporting System. Eur Urol Focus. 2023 Jan;9(1):141-144.
  14. Nishiuchi S, Yagi K, Saito H, Zamami Y, Niimura T, Miyata K, Sakamoto Y, Fukunaga K, Ishida S, Hamano H, Aizawa F, Goda M, Chuma M, Izawa-Ishizawa Y, Nawa H, Yanagawa H, Kanda Y, Ishizawa K. Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis. European Journal of Pharmacology. . 2022 Aug;928:175083.
  15. Higashionna T, Ushio S, Esumi S, Murakawa K, Kitamura Y, Sendo T Retrospective Cohort Study of Clinical Efficacy and Safety of Cefozopran for Treating febrile Neutropenia during Chemotherapy in Patients with Lung Cancer Acta Med Okayama. 2022 Apr;76(2):167-172.
  16. Fujimori T, Hagiya H, Iio K, Higashionna T, Kakehi A, Okura M, Minabe H, Yokoyama Y, Otsuka F, Higashikage A. Vancomycin MIC creep progresses in methicillin-resistant Staphylococcus aureus despite the national antimicrobial stewardship campaign: Single facility data in Japan. J Infect Chemother. 2022 Jul;28(7):918-922.
  17. Takahashi M, Hagiya H, Higashionna T, Nakano Y, Sato K, Haruki Y, Haruki M, Honda H, Ogawa H, Ueda K, Otsuka F Antimicrobial Prescription Practices for Outpatients with Uncomplicated Cystitis in Japan Sci Rep. 2022 Apr 8;12(1):5921.
  18. Yagi K, Sato Y, Sakaguchi S, Goda M, Hamano H, Aizawa F, Shimizu M, Inoue-Hamano A, Nishimori T, Tagi M, Kanno M, Matsuoka-Ando R, Yoshioka T, Matstubara Y, Izawa-Ishizawa Y, Shimizu R, Maruo A, Kuniki Y, Sakamoto Y, Itobayashi S, Zamami Y, Yanagawa H, Ishizawa K. A web-based survey of educational opportunities of medical professionals based on changes in conference design during the COVID-19 pandemic. Educ Inf Technol (Dordr). 2022;27(7):10371-10386.
  19. Kanda M, Goda M, Maegawa A, Yoshioka T, Yoshida A, Miyata K, Aizawa F, Niimura T, Hamano H, Okada N, Sakurada T, Chuma M, Yagi K, Izawa-Ishizawa Y, Yanagawa H, Zamami Y, Ishizawa K. Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis. Clin Transl Sci. 2022 Jul;15(7):1664-1675.
  20. Sato Y, Sakaguchi S, Takechi K, Chuma M, Yagi K, Kane C, Goda M, Hamano H, Aoe Y, Nokihara H, Kubo Y, Hashimoto I, Yanagawa H. Trends in Investigator-Initiated Clinical Studies at a University Hospital after Enforcement of the 2018 Clinical Trials Act in Japan. Biol Pharm Bull. 2022;45(3):374-377.
  21. Zamami Y, Niimura T, Kawashiri T, Goda M, Naito Y, Fukushima K, Ushio S, Aizawa F, Hamano H, Okada N, Yagi K, Miyata K, Takechi K, Chuma M, Koyama T, Kobayashi D, Shimazoe T, Fujino H, Izawa-Ishizawa Y, Ishizawa K. Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. Biomed Pharmacother. 2022 Apr;148:112744.
  22. Mitsuboshi S, Niimura T, Yoshino M, Sakamoto Y, Zamami Y, Ishizawa K. Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database: Int J Clin Pharm. 2022 Feb;44(1):260-263.
  23. Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, Okada N, Asada M, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Yoshioka T, Izawa-Ishizawa Y, Yanagawa H, Tasaki Y, Ishizawa K. Association between statin use and daptomycin-related musculoskeletal adverse events: A mixed approach combining a meta-analysis and a disproportionality analysis. Clinical Infectious Diseases, 2022 Mar.
  24. Mitsuboshi S, Niimura T, Aizawa F, Goda M, Zamami Y, Ishizawa K. Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database. Basic Clin Pharmacol Toxicol. 2022 Feb 16.
  25. Uchida M, Ushio S, Niimura T, Takechi K, Kawazoe H, Hidaka N, Tanaka A, Araki H, Zamami Y, Ishizawa K, Kitamura Y, Sendou T, Kawasaki H, Namba H, Shibata K, Tanaka M, Takatori S. Renin-Angiotensin-Aldosterone System Inhibitors Prevent the Onset of Oxaliplatin-Induced Peripheral Neuropathy: A Retrospective Multicenter Study and in Vitro Evaluation. Biol Pharm Bull. 2022 Feb 1;45(2):226-234.
  26. Sakurada T, Nokihara H, Koga T, Zamami Y, Goda M, Yagi K, Hamano H, Aizawa F, Ogino H, Sato S, Kirino Y, Goto H, Nishioka Y, Ishizawa K. Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study. Oncologist. 2022 Jul 5;27(7):e554-e560.
2021年
  1. Honda H, Hagiya H, Higashionna T, Haruki Y, Haruki M, Kajita S, Mukuda K, Yokoyama Y, Nakano Y, Ogawa H, Morimoto Y, Hanayama Y, Kanda S, Kataoka H, Muguruma H, Otsuka F.: Impact of the day of the week on the discontinuation of broad-spectrum antibiotic prescriptions; a multi-centered observational study. Sci Rep. 11(1):20784, 2021.
  2. Tsukahara H, Higashionna T, Tsuge M, Miyamura J, Kusano N.: Coronavirus disease 2019 in Okayama Prefecture: Looking back and looking forward. Glob Health Med. 3(2):102-106, 2021.
  3. Fujihara M, Shien T, Shien K, Suzawa K, Takeda T, Zhu Y, Mamori T, Otani Y, Yoshioka R, Uno M, Suzuki Y, Abe Y, Hatono M, Tsukioki T, Takahashi Y, Kochi M, Iwamoto T, Taira N, Doihara H, Toyooka S.: YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. Int J Mol Sci. 22(23):12809, 2021.
  4. Tabuchi H, Kitamura Y, Ushio S, Kan S, Wada Y, Sumiyoshi Y, Izushi Y, Miyazaki I, Asanuma M, Sendo T.:Influence of 5-HT2A receptor function on anxiety-like behavior induced by a combination treatment with doxorubicin and cyclophosphamide in rats. Psychopharmacology (Berl). 238(12): 3607-3614, 2021. doi: 10.1007/s00213-021-05979-5.
  5. Kataoka Y, Anan K, Taito S, Tsujimoto Y, Kurata Y, Wada Y, Maruta M, Kanaoka K, Oide S, Takahashi S, Nango E.:Quality of clinical practice guidelines in Japan remains low: a cross-sectional meta-epidemiological study.J Clin Epidemiol. 2021 Jul 2;138:22-31. doi: 10.1016/j.jclinepi.2021.06.025
  6. Morio K, Kurata Y, Kawaguchi-Sakita N, Shiroshita A, Kataoka Y.:Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis. Ann Pharmacother. June 17, 2021. doi: 10.1177/10600280211025792.
  7. Matsumoto D, Ushio S, Wada Y, Noda Y, Esumi S, Izushi Y, Kitamura Y, Sendo T.:Bumetanide prevents diazepam-modified anxiety-like behavior in lipopolysaccharide-treated mice. Eur. J. Pharmacol. 2021 Aug 5;904:174195
  8. Kishi T, Sakuma K, Okuya M, Matsuda Y, Esumi S, Hashimoto Y, Hatano M, Miyake N, Miura I, Mishima K, Iwata N.: Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. Bipolar Disord. 2021 Feb 9. doi: 10.1111/bdi.13053. (Online ahead of print.)
  9. Tsukahara H, Higashionna T, Tsuge M, Miyamura J, Kusano N.COVID-19 in Okayama Prefecture: Looking back and looking forward. Glob Health Med. 2021; 3(2):102-106.